Institutional Investors Control 60% of Altimmune, Inc. (NASDAQ:ALT) and Were Rewarded Last Week After Stock Increased 11%
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24
JMP Securities analyst Jonathan Wolleben maintains $Altimmune(ALT.US)$ with a buy rating, and maintains the target price at $24.According to TipRanks data, the analyst has a success rate of 43.9%
Buy Rating Affirmed for Altimmune on Pemvidutide's Positive Trial Data and Strategic Advancements
Altimmune Spikes After Presenting Data for Obesity Drug
Altimmune Corrects Previous Release; Says Reduction Of Visceral Adipose Tissue (VAT) At Week 48 Adjusted To 28.3% From 25.6%, And Subcutaneous Adipose Tissue Reduction Revised To 19.5% From 20.1%
Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity